Literature DB >> 3532945

Therapy of experimental cerebral nocardiosis with imipenem, amikacin, trimethoprim-sulfamethoxazole, and minocycline.

M E Gombert, T M Aulicino, L duBouchet, G E Silverman, W M Sheinbaum.   

Abstract

A mouse model of cerebral nocardiosis was used to determine relative antibiotic efficacy by reducing bacterial colony counts per gram of brain tissue. The antimicrobial agents employed were demonstrated in vitro to be inhibitory to most strains of Nocardia asteroides at very low concentrations. The agents used in this study were imipenem-cilastatin, amikacin, trimethoprim-sulfamethoxazole, and minocycline. Antibiotics were administered every 4 h for 72 h before animal sacrifice. Bacterial colony counts were assayed at various time points before the completion of therapy. Imipenem-cilastatin and amikacin were the most effective agents tested. Trimethoprim-sulfamethoxazole was less effective than imipenem and amikacin but more effective than minocycline. Minocycline did not eradicate intracerebral organisms and was similar to saline (control) in its effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532945      PMCID: PMC180533          DOI: 10.1128/AAC.30.2.270

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Nocardiosis of the central nervous system.

Authors:  E G KRUEGER; L NORSA; M KENNEY; P A PRICE
Journal:  J Neurosurg       Date:  1954-05       Impact factor: 5.115

2.  In vitro susceptibility of Nocardia asteroides to amikacin.

Authors:  J R Dalovisio; G A Pankey
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Activity of minocycline against Nocardia asteroides: comparison with tetracycline in agar-dilution and standard disc-diffusion tests and with sulfadiazine in an experimental infection of mice.

Authors:  M C Bach; O Gold; M Finland
Journal:  J Lab Clin Med       Date:  1973-05

4.  Recent experiences with nocardial infections.

Authors:  W Rosett; G R Hodges
Journal:  Am J Med Sci       Date:  1978 Nov-Dec       Impact factor: 2.378

5.  Apparent cure of intracranial Nocardia asteroides infection by minocycline.

Authors:  M V Wren; A M Savage; R H Alford
Journal:  Arch Intern Med       Date:  1979-02

6.  Virulence of Nocardia asteroides during its growth cycle.

Authors:  B L Beaman; S Maslan
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

7.  Nocardial infections in the United States, 1972-1974.

Authors:  B L Beaman; J Burnside; B Edwards; W Causey
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

8.  Treatment of experimental nocardiosis in mice: comparison of amikacin and sulfonamide.

Authors:  R J Wallace; E J Septimus; D M Musher; M B Berger; R R Martin
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

9.  Results of therapy in systemic nocardiosis.

Authors:  P J Geiseler; B R Andersen
Journal:  Am J Med Sci       Date:  1979 Nov-Dec       Impact factor: 2.378

Review 10.  Human nocardiosis. A clinical review with selected case reports.

Authors:  W A Curry
Journal:  Arch Intern Med       Date:  1980-06
View more
  13 in total

1.  Antimicrobial susceptibility patterns of Nocardia asteroides.

Authors:  R J Wallace; L C Steele; G Sumter; J M Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  Susceptibility of Nocardia asteroides to new quinolones and beta-lactams.

Authors:  M E Gombert; T M Aulicino; L duBouchet; L R Berkowitz
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  In vitro activities of linezolid against multiple Nocardia species.

Authors:  B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Report of human nocardiosis in Italy between 1993 and 1997.

Authors:  C Farina; P Boiron; I Ferrari; F Provost; A Goglio
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262).

Authors:  K Yazawa; Y Mikami; J Uno
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

Review 6.  Nocardiosis: updates and clinical overview.

Authors:  John W Wilson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

Review 7.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

8.  Therapy of pulmonary nocardiosis in immunocompromised mice.

Authors:  M E Gombert; L B Berkowitz; T M Aulicino; L duBouchet
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Secular trends of nocardia infection over 15 years in a tertiary care hospital.

Authors:  R Matulionyte; P Rohner; I Uçkay; D Lew; J Garbino
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 10.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.